Novartis COPD Drug
Links shared publicly online about this topic
Article > Novartis files COPD drug in Japan
pharmatimes.com — “Article > Novartis files COPD drug in Japan” View full resource at pharmatimes.com
Most Recently Shared on November 27, 2011 at 2:23 pm By:
Michael Blaiss, MD Doctor, Allergist, and Physician
Novartis files COPD drug in Japan http://t.co/hxBlR7iD
Novartis hails longer-lasting COPD drug | InPharm
inpharm.com — “Novartis hails longer-lasting COPD drug | InPharm” View full resource at inpharm.com
Most Recently Shared on September 20, 2010 at 11:21 am By:
Pharmafocus Health News and Pharma
Novartis hails longer-lasting COPD drug http://ht.ly/2GKy5
FDA delays decision on Novartis' COPD drug | InPharm
inpharm.com — “The FDA has delayed its licence decision on Novartis--™ once-daily COPD treatment QAB149 by three months.” View full resource at inpharm.com
Most Recently Shared on March 23, 2011 at 3:52 pm By:
Pharmafocus Health News and Pharma
FDA delays decision on Novartis' COPD drug http://goo.gl/fb/JFT6h
Novartis' COPD drug recommended for FDA approval | InPharm
inpharm.com — “InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.” View full resource at inpharm.com
Most Recently Shared on March 10, 2011 at 9:42 am By:
Pharmafocus Health News and Pharma
Novartis' COPD drug recommended for FDA approval http://goo.gl/fb/U2ZRw
Novartis lung drug better than salmeterol in COPD http://dlvr.it/5Z9cg
reuters.com — “Novartis lung drug better than salmeterol in COPD http://dlvr.it/5Z9cg” View full resource at reuters.com
Most Recently Shared on September 20, 2010 at 6:10 am By:
Novartis lung drug better than salmeterol in COPD http://dlvr.it/5Z9cg
Novartis Announces FDA Approval For Arcapta To Treat COPD Symptoms
rttnews.com — “Novartis AG (NVS), Friday announced that the US Food and Drug Administration has approved once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.” View full resource at rttnews.com
Most Recently Shared on July 2, 2011 at 2:30 am By:
Michael Blaiss, MD Doctor, Allergist, and Physician
Novartis Announces FDA Approval For Arcapta To Treat COPD Symptoms, once a day bronchodilator - http://goo.gl/cd9hS
Novartis lung drug better than salmeterol in COPD - QualityPoint Technologies
qualitypointtech.net — “ZURICH (Reuters) - Novartis' lung drug Onbrez Breezhaler allows patients with a deadly lung disease to breathe more easily than a current mainstay treatment, adding to positive sentiment surrounding the Swiss drugmaker. (Source: Reuters: Health)” View full resource at qualitypointtech.net
Most Recently Shared on September 20, 2010 at 7:49 am By:
Novartis lung drug better than salmeterol in COPD: ZURICH (Reuters) - Novartis' lung drug Onbrez Breezhaler allow... http://bit.ly/9ThYc9
Novartis launches once-daily COPD drug in US - NEWS - General articles - Pharmaceutical Industry - PMLiVE
pmlive.com — “Pharmaceutical Industry | NEWS | General | Novartis launches once-daily COPD drug in US - Arcapta Neohaler could be blockbuster if pharma company makes most of product’s combination potential | PMLiVE” View full resource at pmlive.com
Most Recently Shared on March 20, 2012 at 2:39 pm By:
eyeonfda Pharma and Health Lawyer
RT @dominic_tyer: RT @pmlivecom: Novartis launches once-daily #COPD drug in US http://t.co/TapSx5wV #pharma
Onbrez Breezhaler From Novartis Provides Greater Clinical Benefits Than Tiotropium in New Study of COPD Patients - Drugs.com MedNews
drugs.com — “Study shows Onbrez Breezhaler superior to tiotropium in reducing breathlessness and use of rescue medication and in improving overall health status 1 INTENSITY” View full resource at drugs.com
Most Recently Shared on November 3, 2010 at 3:09 pm By:
Drugs and Devices OW OW Health
Onbrez Breezhaler From Novartis Provides Greater Clinical Benefits Than Tiotropium in New Study of COPD Patie... http://bit.ly/ab5rWP #drug
Novartis Studies Show Onbrez Breezhaler Plus Tiotropium Is More Effective Than Tiotropium Alone in Treatment of COPD - Drugs.com MedNews
drugs.com — “Phase III studies show once-daily Onbrez Breezhaler plus tiotropium improved lung function (measured by trough FEV1) by up to 230 mL from baseline 1 Reported in” View full resource at drugs.com
Most Recently Shared on May 16, 2011 at 3:10 pm By:
Drugs and Devices OW OW Health
Novartis Studies Show Onbrez Breezhaler Plus Tiotropium Is More Effective Than Tiotropium Alone in Treatme... http://bit.ly/lkV4To #drug
Medical News: FDA Panel to Vote on Approval, Dosing for COPD Drug - in Pulmonology, COPD from MedPage Today
medpagetoday.com — “WASHINGTON -- An FDA advisory panel will vote Tuesday on whether a novel long-acting beta-adrenergic agonist is safe and effective at treating airflow obstruction in patients with chronic obstructive” View full resource at medpagetoday.com
Most Recently Shared on March 8, 2011 at 3:07 pm By:
John Carroll Health Communicator
FDA advisory panel meets on Novartis' COPD drug indicatarol today. Key question centers on dosage in second review. http://bit.ly/eB0RXx
Onbrez Breezhaler from Novartis provides greater clinical benefits than tiotropium in new study of COPD patients
novartis.com — “Onbrez Breezhaler from Novartis provides greater clinical benefits than tiotropium in new study of COPD patients” View full resource at novartis.com
Most Recently Shared on November 3, 2010 at 6:22 am By:
INTENSITY study from Novartis presented at #CHEST10 provides new H2H data comparing two COPD drugs http://bit.ly/cN61nM
FDA OKs Asthma Drug for COPD
webmd.com — “The fda has approved the use of symbicort pmdi (pressurized metered-dose inhaler), which is used to treat asthma, to treat chronic obstructive pulmonary disorder (copd).” View full resource at webmd.com
Most Recently Shared on November 25, 2009 at 4:09 pm By:
Just reading: FDA approves asthma drug to treat COPD http://bit.ly/5UxYFw
FDA informs Novartis of extension to US regulatory review period for QAB149, a novel once-daily bronchodilator for treatment of COPD
novartis.com — “FDA informs Novartis of extension to US regulatory review period for QAB149, a novel once-daily bronchodilator for treatment of COPD” View full resource at novartis.com
Most Recently Shared on March 23, 2011 at 3:24 pm By:
eyeonfda Pharma and Health Lawyer
#FDA extends regulatory review period for Novartis #COPD drug http://ow.ly/4kMob
Article > Novartis: Onbrez beats Spiriva for COPD quality of life
pharmatimes.com — “Article > Novartis: Onbrez beats Spiriva for COPD quality of life” View full resource at pharmatimes.com
Most Recently Shared on October 3, 2011 at 6:03 pm By:
Michael Blaiss, MD Doctor, Allergist, and Physician
Novartis: Onbrez beats Spiriva for COPD quality of life - http://t.co/Rdx0nvNc
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Michael Blaiss, MD
Allergist. Past President of the American College of Allergy, Asthma, and Immunology
-
Pharmafocus
Monthly pharmaceutical, biotech & healthcare news publication for Europe. For pharma & biotech jobs follow @inpharmjobs. Twitter accounts run by @dominic_tyer
-
Pharmafocus
Monthly pharmaceutical, biotech & healthcare news publication for Europe. For pharma & biotech jobs follow @inpharmjobs. Twitter accounts run by @dominic_tyer
Advertisement
